Advanced

Cost of treatment of schizophrenia in six European countries

Salize, Hans Joachim; McCabe, Rosemarie; Bullenkamp, Jens; Hansson, Lars LU ; Lauber, Christoph; Martinez-Leal, Rafael; Reinhard, Iris; Roessler, Wulf; Svensson, Bengt LU and Torres-Gonzalez, Francisco, et al. (2009) In Schizophrenia Research 111(1-3). p.70-77
Abstract
Background and aims: As part of an RCT in six European sites, the direct mental health care cost for 422 patients with schizophrenia was analysed according to how total and medication costs differed across sites and which variables were likely to predict total or service-specific costs. Method: Service use was recorded continuously during a 12-month follow-up. Prescribed psychotropic medication was recorded at baseline and 12 months later. Service use data were transformed into EURO, log-transformed and analysed using linear regression models. Results: Although samples were homogeneous, large inter-site cost differences were found (annual means ranging from 2958 E in Spain up to 36978 E in Switzerland). Psychopharmacologic costs were much... (More)
Background and aims: As part of an RCT in six European sites, the direct mental health care cost for 422 patients with schizophrenia was analysed according to how total and medication costs differed across sites and which variables were likely to predict total or service-specific costs. Method: Service use was recorded continuously during a 12-month follow-up. Prescribed psychotropic medication was recorded at baseline and 12 months later. Service use data were transformed into EURO, log-transformed and analysed using linear regression models. Results: Although samples were homogeneous, large inter-site cost differences were found (annual means ranging from 2958 E in Spain up to 36978 E in Switzerland). Psychopharmacologic costs were much more constant across sites than costs for other services. Total costs were associated more with region or socio-demographic characteristics than with disorder related parameters. Conclusions: The findings confirm remarkable differences in direct costs of patients with schizophrenia across Europe. However, the relative stability of medication costs suggests a need to analyse mechanisms that influence service-specific costs for schizophrenia. (C) 2009 Elsevier B.V. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Schizophrenia, Community care, Service utilization, Psychopharmacologic costs, Cost of care
in
Schizophrenia Research
volume
111
issue
1-3
pages
70 - 77
publisher
Elsevier
external identifiers
  • wos:000266745900010
  • scopus:67349277684
ISSN
0920-9964
DOI
10.1016/j.schres.2009.03.027
language
English
LU publication?
yes
id
7f73adc2-a991-4f8f-a43d-567c60435222 (old id 1441870)
date added to LUP
2009-07-27 15:06:53
date last changed
2017-10-01 03:46:22
@article{7f73adc2-a991-4f8f-a43d-567c60435222,
  abstract     = {Background and aims: As part of an RCT in six European sites, the direct mental health care cost for 422 patients with schizophrenia was analysed according to how total and medication costs differed across sites and which variables were likely to predict total or service-specific costs. Method: Service use was recorded continuously during a 12-month follow-up. Prescribed psychotropic medication was recorded at baseline and 12 months later. Service use data were transformed into EURO, log-transformed and analysed using linear regression models. Results: Although samples were homogeneous, large inter-site cost differences were found (annual means ranging from 2958 E in Spain up to 36978 E in Switzerland). Psychopharmacologic costs were much more constant across sites than costs for other services. Total costs were associated more with region or socio-demographic characteristics than with disorder related parameters. Conclusions: The findings confirm remarkable differences in direct costs of patients with schizophrenia across Europe. However, the relative stability of medication costs suggests a need to analyse mechanisms that influence service-specific costs for schizophrenia. (C) 2009 Elsevier B.V. All rights reserved.},
  author       = {Salize, Hans Joachim and McCabe, Rosemarie and Bullenkamp, Jens and Hansson, Lars and Lauber, Christoph and Martinez-Leal, Rafael and Reinhard, Iris and Roessler, Wulf and Svensson, Bengt and Torres-Gonzalez, Francisco and van den Brink, Rob and Wiersma, Durk and Priebe, Stefan},
  issn         = {0920-9964},
  keyword      = {Schizophrenia,Community care,Service utilization,Psychopharmacologic costs,Cost of care},
  language     = {eng},
  number       = {1-3},
  pages        = {70--77},
  publisher    = {Elsevier},
  series       = {Schizophrenia Research},
  title        = {Cost of treatment of schizophrenia in six European countries},
  url          = {http://dx.doi.org/10.1016/j.schres.2009.03.027},
  volume       = {111},
  year         = {2009},
}